Komipharm In Spotlight As It Files For Emergency Trials Against Coronavirus
Komipharm files for emergency clinical trial of its investigative drug to treat coronavirus pneumonia, which is poised to become the first such study by a Korean company.
You may also be interested in...
As South Korean companies jump into the development of vaccines and drugs for the coronavirus, they also call for stronger government support and increased collaboration between the state and private sectors.
Although the pandemic could slightly delay CrystalGenomics’ business and R&D plans, the South Korean biotech is still hopeful this year will bring long-awaited progress for anticancer candidate ivaltinostat as well as discovery of its potential as a treatment for the new coronavirus.
A trade institute's recent report emphasizes that government support is still needed although South Korean CRO industry has grown sharply in recent years and suggests ways to improve global competitiveness.